Year | 2014 | 2015 | 2016 |
---|---|---|---|
COPD patients in HIRA claim data | n = 569,253 | n = 557,682 | n = 539,708 |
Demographics | |||
 Age, mean ± SD | 66.8 ± 13.2 | 67.5 ± 13.2 | 68.2 ± 13.2 |
 Sex, male (%) | 349,505 (61.4) | 341,160 (61.2) | 328,170 (60.8) |
Clinical practice parameters | |||
 PFT conduction (%) | 191,465 (33.6) | 206,519 (37.0) | 208,952 (38.7) |
 Inhaled LAMA prescription (%) | 78,044 (13.7) | 90,871 (16.3) | 94,501 (17.5) |
 Inhaled LABA prescription (%) | 144,130 (25.3) | 153,830 (27.6) | 148,101 (27.4) |
 ICS prescription (%) | 305,744 (53.7) | 295,227 (52.9) | 283,804 (52.6) |
 SABA prescription (%) | 90,031 (15.8) | 69,349 (12.4) | 67,717 (12.6) |
Prognosis | |||
 Frequency of admission for COPD /yr, mean ± SD | 0.146 ± 0.773 | 0.147 ± 0.791 | 0.162 ± 0.869 |
 Medical cost for COPD management, mean ± SD (USD) | 335.5 ± 1665.2 | 375.7 ± 1943.6 | 423.2 ± 2124.7 |
 All-cause mortality in the next year (%) | 17,950 (3.2) | 21,114 (3.8) | 23,417 (4.3) |